ArticleInternational ophthalmology2025
Lid wiper epitheliopathy and ocular surface dysfunction in benign essential blepharospasm before and after botulinum toxin-A injection.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bridging the gap: A new perspective on lid wiper epitheliopathy and meibomian gland inversion.Eye (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate ocular surface dysfunction in patients with benign essential blepharospasm (BEB) by evaluating lid wiper epitheliopathy (LWE) and ocular surface parameters and to compare these findings with those of normal and dry eye controls. Additionally, we aimed to assess the impact of botulinum toxin (BTX-A) injection on ocular surface parameters and LWE.
methodsThis study included BEB patients and age- and sex-matched healthy and dry-eye controls. LWE grading and ocular surface parameters were assessed, including OSDI score, Schirmer's I test, tear break-up time (TBUT), corneal staining, eyelid margin abnormalities, and meibomian gland function. Patients with BEB received BTX-A injections, and measurements were repeated 1, 3, and 6 months post-treatment.
resultsCompared to control groups, the BEB group exhibited significantly increased OSDI scores, corneal surface staining, eyelid margin abnormalities, meibomian expression, meibography scores, meibomian gland loss, and LWE grades of the upper and lower eyelid (p < 0.05) while TBUT and Schirmer's I test values were significantly decreased (p < 0.05). Significant positive correlations were observed between the severity and frequency of BEB and ocular surface dysfunction, including LWE (p < 0.05). LWE severity was significantly correlated with age, female gender, and ocular surface parameters (p < 0.05). BTX-A injection significantly improved ocular surface parameters for 6 months, but LWE reduction was insignificant at 6 months (p < 0.05).
conclusionLWE was identified as a significant contributor to conjunctivocorneal damage in BEB. Furthermore, BTX-A injection effectively treats ocular surface dysfunction, including LWE.
Indexed as
Identifiers
41231346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.